• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高细胞毒性的钼配合物具有强烈的代谢效应,可抑制小鼠肿瘤生长。

Highly Cytotoxic Molybdenocenes with Strong Metabolic Effects Inhibit Tumour Growth in Mice.

机构信息

Institute of Inorganic Chemistry, University of Vienna, Währinger Straße 42, 1090, Vienna, Austria.

Research Cluster "Translational Cancer Therapy Research", Währinger Straße 42, 1090, Vienna, Austria.

出版信息

Chemistry. 2023 Jan 18;29(4):e202202648. doi: 10.1002/chem.202202648. Epub 2022 Nov 29.

DOI:10.1002/chem.202202648
PMID:36222279
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10099754/
Abstract

A series of six highly lipophilic Cp-substituted molybdenocenes bearing different bioactive chelating ligands was synthesized and characterized by NMR spectroscopy, mass spectrometry and X-ray crystallography. In vitro experiments showed a greatly increased cytotoxic potency when compared to the non-Cp-substituted counterparts. In vivo experiments performed with the dichlorido precursor, (Ph C-Cp) MoCl and the in vitro most active complex, containing the thioflavone ligand, showed an inhibition of tumour growth. Proteomic studies on the same two compounds demonstrated a significant regulation of tubulin-associated and mitochondrial inner membrane proteins for both compounds and a strong metabolic effect of the thioflavone containing complex.

摘要

合成并通过 NMR 光谱、质谱和 X 射线晶体学对一系列六种具有不同生物活性螯合配体的高度亲脂性 Cp 取代的钼配合物进行了表征。与非 Cp 取代的对应物相比,体外实验显示出极大地增加了细胞毒性效力。用二氯代前体(Ph C-Cp)MoCl 和体外最活跃的配合物(含硫代黄酮配体)进行的体内实验表明抑制了肿瘤生长。对相同的两种化合物进行的蛋白质组学研究表明,两种化合物的微管相关蛋白和线粒体内膜蛋白均受到显著调节,并且含硫代黄酮的配合物具有强烈的代谢作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/bd521f7fe089/CHEM-29-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/6bc8b160024c/CHEM-29-0-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/03edabb7e7d9/CHEM-29-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/bd521f7fe089/CHEM-29-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/6bc8b160024c/CHEM-29-0-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/03edabb7e7d9/CHEM-29-0-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd39/10099754/bd521f7fe089/CHEM-29-0-g002.jpg

相似文献

1
Highly Cytotoxic Molybdenocenes with Strong Metabolic Effects Inhibit Tumour Growth in Mice.高细胞毒性的钼配合物具有强烈的代谢效应,可抑制小鼠肿瘤生长。
Chemistry. 2023 Jan 18;29(4):e202202648. doi: 10.1002/chem.202202648. Epub 2022 Nov 29.
2
Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.含P^P螯合配体的半夹心铱(III)和钌(II)配合物:一类具有异常氧化还原特性的新型强效抗癌剂。
Inorg Chem. 2018 Feb 19;57(4):1705-1716. doi: 10.1021/acs.inorgchem.7b01959. Epub 2018 Feb 5.
3
Water-soluble molybdenocene complexes with both proliferative and antiproliferative effects on cancer cell lines and their binding interactions with human serum albumin.对癌细胞系具有增殖和抗增殖作用的水溶性茂金属钼配合物及其与人血清白蛋白的结合相互作用。
J Biol Inorg Chem. 2009 Sep;14(7):1109-17. doi: 10.1007/s00775-009-0554-0. Epub 2009 Jun 18.
4
The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate Effects.首例抗癌三(吡唑基)硼酸盐钼(IV)配合物:体外和体内试验- O,O-、S,O-和 N,N-螯合效应的比较。
Chemistry. 2020 Feb 17;26(10):2211-2221. doi: 10.1002/chem.201903605. Epub 2019 Nov 19.
5
High in vitro and in vivo antitumor activities of Ln(III) complexes with mixed 5,7-dichloro-2-methyl-8-quinolinol and 4,4'-dimethyl-2,2'-bipyridyl chelating ligands.Ln(III) 配合物与混合 5,7-二氯-2-甲基-8-喹啉醇和 4,4'-二甲基-2,2'-联吡啶螯合配体的高体外和体内抗肿瘤活性。
Eur J Med Chem. 2019 May 1;169:103-110. doi: 10.1016/j.ejmech.2019.02.066. Epub 2019 Mar 5.
6
A half-sandwich Ta dichlorido complex containing an O,N,O'-tridentate Schiff base ligand: synthesis, crystal structure and in vitro cytotoxicity.一种含有O,N,O'-三齿席夫碱配体的半三明治型钽二氯配合物:合成、晶体结构及体外细胞毒性
Acta Crystallogr C Struct Chem. 2019 Mar 1;75(Pt 3):248-254. doi: 10.1107/S2053229619001323. Epub 2019 Feb 8.
7
Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.具有 C^N-螯合配体的高活性半三明治有机铱(III)抗癌配合物的构效关系。
J Inorg Biochem. 2019 Feb;191:1-7. doi: 10.1016/j.jinorgbio.2018.11.007. Epub 2018 Nov 10.
8
Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase.α-N-杂环硫代半卡巴腙的镓(III)和铁(III)配合物:合成、表征、细胞毒性以及与核糖核苷酸还原酶的相互作用
J Med Chem. 2007 Mar 22;50(6):1254-65. doi: 10.1021/jm0612618. Epub 2007 Feb 22.
9
Addition of ethynylferrocene to transition-metal complexes containing a chelating 1,2-dicarba-closo-dodecaborane-1,2-dichalcogenolate ligand--in vitro cooperativity of a ruthenium compound on cellular uptake of an anticancer drug.将乙炔基二茂铁添加到含有螯合的1,2-二碳-闭式-十二硼烷-1,2-二硫属元素醇盐配体的过渡金属配合物中——一种钌化合物在抗癌药物细胞摄取方面的体外协同作用。
Dalton Trans. 2009 Jan 14(2):285-90. doi: 10.1039/b810831e. Epub 2008 Nov 10.
10
Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.通过 N,O-螯合配体调节锇芳烃配合物的水解水相化学以实现癌细胞毒性。
J Am Chem Soc. 2007 Mar 21;129(11):3348-57. doi: 10.1021/ja068335p. Epub 2007 Feb 24.

引用本文的文献

1
Anticancer Tungstenocenes with a Diverse Set of (-), (,-) and (,-) Chelates-A Detailed Biological Study Using an Improved Evaluation via 3D Spheroid Models.具有多种(-)、(,-)和(,-)螯合物的抗癌钨茂——通过3D球体模型改进评估的详细生物学研究
Pharmaceutics. 2023 Jul 3;15(7):1875. doi: 10.3390/pharmaceutics15071875.

本文引用的文献

1
Die Wechselwirkung mit ribosomalen Proteinen begleitet die Stressinduktion des Wirkstoffkandidaten BOLD-100/KP1339 im endoplasmatischen Retikulum.候选药物BOLD-100/KP1339在内质网中诱导应激时伴有与核糖体蛋白的相互作用。
Angew Chem Weinheim Bergstr Ger. 2021 Mar 1;133(10):5121-5126. doi: 10.1002/ange.202015962. Epub 2021 Feb 1.
2
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance.一种克服基于谷胱甘肽的奥沙利铂耐药性的铂(IV)前药策略。
Commun Chem. 2022 Apr 6;5(1):46. doi: 10.1038/s42004-022-00661-z.
3
Arene Variation of Highly Cytotoxic Tridentate Naphthoquinone-Based Ruthenium(II) Complexes and In-Depth In Vitro Studies.
基于高细胞毒性三齿萘醌的钌(II)配合物的芳烃变体及深入的体外研究
Pharmaceutics. 2022 Nov 15;14(11):2466. doi: 10.3390/pharmaceutics14112466.
4
Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD-100/KP1339 in the Endoplasmic Reticulum.与核糖体蛋白的相互作用伴随着抗癌金属药物 BOLD-100/KP1339 在内质网中的应激诱导。
Angew Chem Int Ed Engl. 2021 Mar 1;60(10):5063-5068. doi: 10.1002/anie.202015962. Epub 2021 Feb 1.
5
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase.代谢可塑性通过上调葡萄糖-6-磷酸脱氢酶赋予胰腺癌对厄洛替尼的抗性。
Cancer Metab. 2020 Sep 21;8:19. doi: 10.1186/s40170-020-00226-5. eCollection 2020.
6
An Organometallic Gold(I) Bis-N-Heterocyclic Carbene Complex with Multimodal Activity in Ovarian Cancer Cells.一种具有多模式活性的金(I)双-N-杂环卡宾配合物在卵巢癌细胞中的应用。
Chemistry. 2020 Dec 1;26(67):15528-15537. doi: 10.1002/chem.202003495. Epub 2020 Nov 3.
7
The diverse mechanisms and anticancer potential of naphthoquinones.萘醌类化合物的多种作用机制及抗癌潜力
Cancer Cell Int. 2019 Aug 2;19:207. doi: 10.1186/s12935-019-0925-8. eCollection 2019.
8
Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System.抑制葡萄糖-6-磷酸脱氢酶通过氧化还原系统逆转肺癌细胞的顺铂耐药性。
Front Pharmacol. 2018 Jan 31;9:43. doi: 10.3389/fphar.2018.00043. eCollection 2018.
9
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?p53 如何诱导细胞凋亡,以及这与 p53 介导的肿瘤抑制有何关系?
Cell Death Differ. 2018 Jan;25(1):104-113. doi: 10.1038/cdd.2017.169. Epub 2017 Nov 17.
10
An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin.一种有机钌抗癌剂对网蛋白显示出出乎意料的靶向选择性。
Angew Chem Int Ed Engl. 2017 Jul 3;56(28):8267-8271. doi: 10.1002/anie.201702242. Epub 2017 May 26.